Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLSD NASDAQ:MRKR NASDAQ:OBSV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.41$1.19$0.37▼$14.09$2.15M2.04220,545 shsN/AMRKRMarker Therapeutics$1.11-5.9%$1.40$0.81▼$2.46$19.67M1.4557,843 shs39,203 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs4,102 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%0.00%0.00%0.00%-94.31%MRKRMarker Therapeutics-5.93%-10.48%-23.97%-23.97%-21.28%OBSVObsEva0.00%0.00%0.00%0.00%+100.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLSDClearside Biomedical$0.41$1.19$0.37▼$14.09$2.15M2.04220,545 shsN/AMRKRMarker Therapeutics$1.11-5.9%$1.40$0.81▼$2.46$19.67M1.4557,843 shs39,203 shsOBSVObsEva$0.00$0.08▼$2.14$7.94M0.688.94 million shs4,102 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLSDClearside Biomedical0.00%0.00%0.00%0.00%-94.31%MRKRMarker Therapeutics-5.93%-10.48%-23.97%-23.97%-21.28%OBSVObsEva0.00%0.00%0.00%0.00%+100.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLSDClearside Biomedical 1.50ReduceN/AN/AMRKRMarker Therapeutics 2.25Hold$10.00800.90% UpsideOBSVObsEva 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLSD, OBSV, and MRKR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026MRKRMarker Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/20/2026MRKRMarker Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLSDClearside Biomedical$3.33M0.64N/AN/A($7.68) per share-0.05MRKRMarker Therapeutics$3.55M5.21N/AN/A$1.01 per share1.10OBSVObsEvaN/AN/AN/AN/A$0.41 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLSDClearside Biomedical-$34.35M-$5.19N/AN/AN/A-665.19%N/A-124.15%N/AMRKRMarker Therapeutics-$12.16M-$0.61N/AN/AN/A-343.03%-73.29%-59.70%8/13/2026 (Estimated)OBSVObsEva-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/ALatest CLSD, OBSV, and MRKR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026MRKRMarker Therapeutics-$0.25N/AN/AN/A$0.68 millionN/A5/15/2026Q1 2026MRKRMarker Therapeutics-$0.18-$0.16+$0.02-$0.16$0.78 million$0.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLSDClearside BiomedicalN/AN/AN/AN/AN/AMRKRMarker TherapeuticsN/AN/AN/AN/AN/AOBSVObsEvaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLSDClearside BiomedicalN/A3.873.87MRKRMarker TherapeuticsN/A4.794.79OBSVObsEvaN/A0.610.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLSDClearside Biomedical18.75%MRKRMarker Therapeutics22.39%OBSVObsEva17.52%Insider OwnershipCompanyInsider OwnershipCLSDClearside Biomedical6.70%MRKRMarker Therapeutics5.70%OBSVObsEva14.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLSDClearside Biomedical305.23 million4.89 millionOptionableMRKRMarker Therapeutics6016.67 million15.72 millionNot OptionableOBSVObsEva5077.97 million66.74 millionNot OptionableCLSD, OBSV, and MRKR HeadlinesRecent News About These CompaniesCritical Review: ObsEva (NASDAQ:OBSV) & PyroGenesis Canada (NASDAQ:PYRGF)July 20, 2026 | americanbankingnews.comObsEva files uterine fibroid drug in US, chasing AbbVie, MyovantAugust 31, 2024 | pharmaphorum.comPObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of ListinApril 3, 2024 | globenewswire.comObsEva Announces Update on Board of DirectorsMarch 19, 2024 | globenewswire.comObsEva Announces Wind-Down of Operations and Notifies SIX that it Will Lack the Resources to Establish Audited IFRS Financial Statements for 2023February 28, 2024 | globenewswire.comObsEva Stock (OTC:OBSEF) Dividends: History, Yield and DatesFebruary 25, 2024 | benzinga.comObsEva SA OBSNNovember 11, 2023 | morningstar.comMObsEva SA OBSEFNovember 11, 2023 | morningstar.comMObsEva (NASDAQ: OBSV)June 18, 2023 | fool.comTocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserverMay 10, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo FinanceMay 2, 2023 | news.google.comNObsEva Says Fabien De Ladonchamps Is New CEO - NasdaqMay 2, 2023 | news.google.comNObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswireMay 2, 2023 | news.google.comNGameto Appoints Teri Loxam as Chief Financial Officer - citybizApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Marketscreener.comApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - Yahoo FinanceApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - BenzingaApril 28, 2023 | news.google.comNObsEva Annual Report 2022 - EIN NewsApril 28, 2023 | news.google.comNGameto Expands Executive Team with the Addition of Teri Loxam as ... - PR NewswireApril 28, 2023 | news.google.comNEndometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital JournalApril 26, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLSD, OBSV, and MRKR Company DescriptionsClearside Biomedical NASDAQ:CLSDClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Marker Therapeutics NASDAQ:MRKR$1.11 -0.07 (-5.93%) Closing price 07/29/2026 04:00 PM EasternExtended Trading$1.10 -0.01 (-0.45%) As of 07/29/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.ObsEva NASDAQ:OBSVObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why SK hynix Could Be the Best AI Chip Stock to Buy Now Why Bloom Energy May Be the Most Important AI Infrastructure Stock Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead? Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters Broadcom’s $200 Billion Samsung Deal Shows How Costly the AI Memory Race Has Become Meta’s AI Spending Problem Just Found a BlackRock Solution Carrier Earnings Could Send the Stock to a New All-Time High Amazon’s Satellite Push Raises the Stakes for SpaceX and AST SpaceMobile Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
